Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Women and Alzheimer’s Disease Subject of Giving Tuesday Webinar

Alzheimer’s Disease Research Foundation

Cure Alzheimer’s Fund will host Dr. Liisa Galea for a Giving Tuesday webinar on her research into women and Alzheimer’s disease. In this pre-recorded webinar, Dr. Galea presents her research on sex-based differences into the causes of Alzheimer's disease and discusses her findings with Meg Smith, CEO of Cure Alzheimer's Fund. Dr. Liisa Galea is the Treliving Family Chair in Women’s Mental Health at the Centre for Addiction and Mental Health (CAMH) in Toronto, Canada and a Professor of Psychiatry at the University of Toronto. Dr. Galea is a world-renowned expert in sex hormone influences on brain and behavior, with a focus on dementia and stress-related psychiatric disorders. Her research examines the intersection of hormones, and stress on brain plasticity in males and females. “Women develop Alzheimer's disease at twice the rate of men. Dr. Galea’s research into why women are more susceptible to Alzheimer’s and what is driving increased risk is impressive,” said CEO Smith. “She is a tireless advocate for women’s health research and for sex and gender-based analysis to improve cognitive aging for both women and men. We are lucky to hear from her.” “There is a lot of talk about precision medicine, the idea that we can tailor treatments based on our genes. But we rarely talk about how different treatments might be needed to combat neurodegenerative diseases like Alzheimer’s based on our sex,” said Galea. “The top three risk factors for late onset sporadic Alzheimer’s disease include APOE4 genotype and female sex. If you are an APOE4 carrier and a female you have an even greater risk of developing Alzheimer’s disease than if you are male carrier. Why not harness this information to see whether we can discover new therapies to combat this devastating illness. It’s time we figured out how sex plays a role, not only in the risk and progression of Alzheimer’s disease, but whether or not, different treatments may need to be tailored by sex.” For more information and to view the webinar, please visit Cure Alzheimer’s Fund at CureAlz.org and https://bit.ly/49jqQuO for the webinar. The webinar takes place during Alzheimer’s Awareness Month in November. It is estimated that more than 6.5 million Americans are currently living with Alzheimer’s disease two-thirds of those who are afflicted are women. It is projected that the share of adults 65 and older in the US population will rise to 22 percent by 2050. With age as the biggest risk factor, Alzheimer’s disease is poised to place an unmanageable financial burden on the US healthcare system, caregivers, and loved ones. About Cure Alzheimer’s Fund Cure Alzheimer’s Fund is a non-profit dedicated to funding the most promising research to prevent, slow, or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has provided grants to the world’s leading researchers and contributed more than $180 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimer’s disease. Cure Alzheimer’s Fund has received a 4-star rating for more than 12 consecutive years from Charity Navigator. With 100 percent of funds raised going to support research, Cure Alzheimer’s Fund has been able to provide grants to many of the best scientific minds in the field of Alzheimer’s research. For more information, visit https://www.curealz.org/. To learn about our the impact of Alzheimer’s on women and women working towards a cure, visit https://womenandalzheimers.org. Contact Details Barbara Chambers +1 978-417-9890 bchambers@curealz.org Company Website https://www.CureAlz.org

November 27, 2023 05:01 AM Eastern Standard Time

Putting the Brakes on Distracted Driving This Holiday Season

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/-m__hB55lSE The holiday season is here – and that means there will be an increase of motorists on U.S. roadways. With more families hitting the road, it’s an important time to discuss the dangers and consequences of distracted driving. The 2023 Travelers Risk Index on distracted driving found that 70% of consumers feel that distracted driving is more of a problem now than it was over the past few years. Following are additional highlights from the 2023 Travelers Risk Index: · 80% make or receive calls. · 57% use handheld devices. · 28% post on social media. · 27% take photos or videos. The Travelers Institute, the public policy division at Travelers, has been raising awareness of the dangers of distracted driving through its Every Second Matters® campaign – an initiative that began in 2017. Since the campaign started, the Travelers Institute has published a number of whitepapers and resources to help consumers understand the risks and learn how to be safe behind the wheel. The Travelers Institute was joined by Cambridge Mobile Telematics (CMT), the world’s largest telematics solution provider, which regularly publishes new distracted driving data insights and road safety reports throughout the year. According to its new report, The State of Distracted Driving in 2023 & the Future of Road Safety, CMT reports that the 23% surge in distracted driving in 2022 caused an additional 420,000 crashes, 1,000 fatalities, and $10 billion in economic damages. Additionally, a new analysis from CMT shows that distracted driving increased by 9.2% on Thanksgiving Day from 2020 to 2022. For more information, visit TRAVELERSINSTITUTE.ORG AND CMT.AI. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 22, 2023 02:00 PM Eastern Standard Time

Video

News Release

Renovaro Biosciences CEO unveils potential breakthrough therapies and AI partnerships for 2024

Renovaro Biosciences Inc

Renovaro Biosciences CEO Dr Mark Dybul joined Steve Darling from Proactive to share news about the significant progress the company is poised to make following the signing of a definitive agreement to merge with GEDiCube, a UK-based medical AI company renowned for its contributions to the early detection and remission of cancer, as well as expedited drug discovery. GEDiCube is set to rebrand as Renovaro.AI, and together, the entities are looking to hasten diagnosis processes, improve the efficacy of treatments, pioneer new therapies, and broaden the availability of vital technologies for cancer and other diseases. Dybul highlighted to Proactive that while Renovaro is currently concentrated on pancreatic cancer research, plans are afoot to extend their focus to include other solid tumors that are typically associated with a short life expectancy. These will be part of the first human Phase I/IIa studies anticipated to commence by mid-2024. He noted the potential of GEDi Cube’s AI technology to refine the focus of upcoming human trials on those cancers that are most amenable to treatment. Furthermore, the technology is expected to enrich the database of crucial markers for early diagnosis and tracking disease progression, thereby fostering the development of novel iterations of Renovaro’s treatment methodologies and the discovery of completely new therapeutic options. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

November 22, 2023 10:44 AM Eastern Standard Time

Video

Mentor Foster Care Celebrates National Adoption Month this November

Sevita

MENTOR Foster Care, a provider of foster care services and part of the Sevita family, is celebrating National Adoption Month this November. National Adoption Month serves as a reminder of the bonds that form through adoption and the importance of providing children with loving, forever homes. The month honors the significance of family and the diversity of families and the paths which bring them together. It also raises awareness of the many children in need and encourages prospective families to learn more. Currently, there are over 390,000 children in foster care. Of those, the average age is around eight years old. However, children come from many different age groups and can be anywhere from infants to young adults up to 20 years old. They also come from many different backgrounds, situations, and needs and deserve a loving and caring home. Oftentimes, foster care becomes the pathway to permanent adoption, known as foster care adoption. Foster care adoption differs from the temporary foster care system — it represents a stable, reliable placement for children and teens in care and provides them with long-term support when reunification with parents is not an option. Fostering and adoption make long-term positive impacts when children are placed in a safe, loving home. For kids, benefits include trust building, educational support and growth, increased social and emotional skills, more positive longer-term outcomes, and more. Additional information on the benefits of foster care can be found here. The number of children adopted from foster care in FY 2021 was 54,240, a 6% decrease from the year prior (FY 2020) and over an 18% decrease from FY 2019. Additional foster families are needed as many children await their forever homes. Sevita’s Mentor Foster Care programs help foster parents provide an environment where children can thrive. Interested individuals can find a complete guide to becoming a foster parent and how Sevita can support you through the journey here. This National Adoption Month, Sevita and its Mentor Foster Care programs celebrate all foster families supporting children across the country and hopes to inspire others to join in its effort to support the youth who need it most. And for those who have adopted children, through foster care or elsewhere, Sevita shares seven ways to celebrate this month. ### MENTOR Foster Care is part of the Sevita family and has been a trusted provider of foster care services since 1980, when it first began offering services as Massachusetts MENTOR. Today, Mentor Foster Care supports thousands of youth and families in nine U.S. states. Our unique model of foster care places children in loving homes with foster parents who support their healing and growth. Services are tailored to each child’s needs and may include trauma-focused counseling services, family and community activities, case management, life skill building, and skill development and support for foster parents. With the support of a clinical team, case managers, and other supportive staff, foster parents help youth with a wide range of challenges heal after trauma and set a hopeful path for their lives. Learn more at sevita.us/foster. Sevita is a leading provider of community-based specialized health care, inspired by our core values of respect, integrity, inclusion and growth. We provide people with quality services and individualized supports that lead to growth and independence, despite the physical, intellectual, or behavioral challenges they face. We’ve made this our mission for more than 50 years. Today our team members continue to innovate and enhance care for the 50,000+ individuals we serve. sevitahealth.com Contact Details Melissa Patricio media@sevitahealth.com Company Website https://sevitahealth.com/

November 21, 2023 01:00 PM Eastern Standard Time

News Release

Valeo Pharma announces new chief financial officer along with $2 million in cost reductions

Valeo Pharma Inc.

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share details about recent executive changes within the company. Saviuk announced the appointment of Pascal Tougas as the new chief financial officer, succeeding Luc Mainville. Tougas is recognized as a well-experienced senior executive in the pharmaceutical industry, with a robust financial background. His previous tenure at Sanofi Canada for 11 years saw him in various key roles, including Country Head, Trade and Revenue Management, interim Chief Financial Officer Canada, and Director Controlling and Operations Canada, among others. Pascal is also well-qualified academically, holding a bachelor's degree in business administration from HEC Montreal along with a CPA designation. Additionally, Saviuk informed Proactive about Valeo Pharma’s strategic efforts aimed at reducing operational costs as the company advances towards profitability. One significant move in this direction is the realignment of the company’s organizational structure. This realignment is expected to yield cost savings while enhancing the efficiency and timeliness of decision-making within the company. These changes are projected to save the company over $2 million. Contact Details Proactive +1 347-449-0879 na-editorial@proactiveinvestors.com

November 21, 2023 07:41 AM Eastern Standard Time

Video

Cyber budgets fail to meet expectations with only 1% increase on previous year in the U.S., finds S-RM

S-RM

· In 2023, the average cyber budget for large organizations grew by 3.1% YOY globally to USD 27.10 million — but only by 1% YOY in the U.S. · The increase falls below the 5% rise anticipated by Senior IT professionals and their C-suites cited in S-RM’s Cyber Security Insights Report 2023 · Nearly a third (31%) of organizations say lack of budget is a key cybersecurity challenge S-RM, a leading global corporate intelligence and cybersecurity consultancy, today published its Cyber Security Insights Report 2023, which reveals that this year’s cyber budgets for large organizations are falling short of expectations. In 2023, globally the average cyber budget grew to USD 27.10 million, up 3.1% from USD 26.30 million in 2022. In the U.S., budgets grew only by 1%. S-RM’s research shows that senior IT professionals and their C-suites had anticipated a more substantial increase of 5%, which would have seen budgets reach USD 27.60 million. The appetite for more budget comes after a year of rising operational costs – a result of wider economic turbulence – and a growing cyber threat following rapid advancements in generative AI. Cybersecurity departments want more budget to upskill employees (42%) and recruit additional skilled personnel (41%) to accommodate this rising threat. On average, cyber budgets make up a quarter (25%) of an organization's overall IT budget, marking a 1% decrease in share from 2022. This allocation varies across sectors, with Retail being the most generous (28%) and Energy & Utilities allocating the least (18%) toward tackling cyber threats. Navigating tightened purse strings Lack of budget was cited as a key challenge by nearly one third (31%) of organizations. To navigate this, cybersecurity teams have been prioritizing spend in the most ‘value for money’ areas. For the third consecutive year, investment in cyber technology topped the list, though fewer organizations highlighted technology as delivering the value commensurate with its cost in 2023 (49%) than in 2022 (58%). This dip can be attributed to a growing awareness that alongside cybersecurity technology, organizations need to invest in governance and personnel to effectively enable and manage new tech. This is a view more prevalent among IT professionals charged with implementing cyber tech solutions, with only 43% citing technology as ‘high value for money’ compared to 56% of C-suite executives. The findings reflect a misalignment of expectations between the operators of cyber technologies and those a step removed from their day-to-day applications. Organizations are adopting several other strategies to manage cybersecurity with restricted budgets: IT and security optimization - Identifying cost reduction opportunities by making existing processes more efficient to allocate budget for more critical initiatives. Future-focused investment - Investing now in security initiatives for long-term cost savings. Outsourcing - Contracting out IT and security functions to Managed Service Security Providers (MSSPs) or virtual Chief Information Security Officers (vCISOs). Paul Caron, Head of Cybersecurity, Americas at S-RM, said: “It’s reassuring that cybersecurity budgets are still rising in these challenging times, but this level of increase is simply not enough to tackle the growing cyber threat. This year’s increase has failed to meet the expectations of cyber teams and reveals that cyber security may be taking a back seat as its share of the overall IT budget declines. “Navigating ongoing skill shortages and investing in training and development of teams comes at a cost, but cyber professionals are not receiving the budget they need to deliver on these critical initiatives. Organizations will have to continue being cautious with cyber security spend, identifying those ‘value for money’ areas that will enable them to manage emerging cyber threats with tightened purse strings.” For more information, access the full 2023 Cyber Security Insights Report on S-RM's official website here: https://www.s-rminform.com/cyber-security-insights-report-2023 ENDS Notes to Editors: Methodology: The S-RM Cyber Security Insights Report 2023 follows on from our 2022 report, where we seek to understand the specific cybersecurity challenges faced by C-suite leaders and senior IT decision makers. For the 2023 report, we interviewed 602 C-Suite and senior IT professionals on the most pressing cyber challenges, cyber security incidents, and cyber budgets over the past year. For more information, access the full 2023 Cyber Security Insights Report on S-RM's official website here: https://www.s-rminform.com/cyber-security-insights-report-2023 About S-RM S-RM is a global corporate intelligence and cybersecurity consultancy with expertise in insurance, cybersecurity, and cyber response. Headquartered in London, S-RM works across 9 international offices and advises companies ranging from blue-chip corporates to large financial institutions, and beyond. To find out more about S-RM, visit https://www.s-rminform.com/ Contact Details Meir Kahtan +1 917-864-0800 mkahtan@rcn.com

November 20, 2023 02:00 PM Eastern Standard Time

News Release

Tonix Pharmaceuticals' CEO reveals next-generation COVID vaccine technology chosen for key program

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr Seth Lederman recently joined Steve Darling from Proactive to share exciting news about their COVID vaccine, TNX-1800, selected for testing in Project Next Gen, a White House initiative managed by the Department of Health and Human Services, NIH, and NIAID. The vaccine is based on a live virus platform, providing a unique approach to waking up the immune system. Live virus vaccines, like TNX-1800, offer more durable immunity that lasts a long time and can potentially block virus transmission, addressing limitations seen in mRNA vaccines. This choice of TNX-1800 is a testament to Tonix's nearly decade-long dedication to vaccine development. The technology platform can also be adapted to protect against other infectious diseases, such as monkeypox, smallpox, and tuberculosis, making it a versatile solution for future pandemics. This development highlights the significance of vaccine platforms for tackling various infectious threats. Tonix's approach promises to offer more robust, long-lasting immunity and potential transmission prevention, which could revolutionize our approach to infectious disease control. The platform's adaptability positions it as a valuable tool for future vaccine strategies. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

November 20, 2023 01:57 PM Eastern Standard Time

Video

News Release

Tonix Pharmaceuticals finish Phase 3 trial of TNX-102 SL for management of Fibromyalgia

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr Seth Lederman recently joined Steve Darling from Proactive to shed light on the latest developments in their research efforts. The company has successfully concluded the clinical phase of a Phase 3 registration-quality study for TNX-102 SL, a drug developed for the management of fibromyalgia. This study, which is double-blind and placebo-controlled, saw the enrollment of 457 patients across various sites in the United States. Lederman conveyed to Proactive that the topline results from this study are anticipated by late December. Should the results be favorable, this trial is expected to be the conclusive well-controlled efficacy trial needed for the submission of a New Drug Application to the U.S. Food and Drug Administration. The urgency and importance of this development are underscored by the fact that an estimated 6-12 million individuals in the US are afflicted with fibromyalgia, a condition that predominantly affects women. In addition to the TNX-102 study, Lederman also discussed another significant milestone: the enrollment of the first participant in a Phase 2 study, supported by the Department of Defense, focusing on TNX-1900 for the improvement of bone health in children with autism spectrum disorder. This investigator-initiated trial represents a foray into addressing the complex needs of children with autism, potentially offering a new therapeutic avenue to enhance their quality of life. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

November 20, 2023 01:53 PM Eastern Standard Time

Video

Oxford Cannabinoid Technologies strengthens board with CMO Dr. Tim Corn

Oxford Cannabinoid Technologies Holdings PLC

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF) CEO Clarissa Sowemimo Coker and CMO Dr Tim Corn speak to Thomas Warner from Proactive after the pharmaceutical group announced the appoint of Corn to its board of directors. The move follows his appointment as Chief Medical Officer in June 2023. Sowemimo-Coker highlights the importance of having a clinician on the board of a biopharmaceutical company. The appointment follows the successful announcement of Phase I single ascending dose results in October, reflecting OCT's commitment to addressing unmet medical needs with novel therapeutic approaches. Dr. Corn cites the combination of addressing unmet medical needs and the use of a novel cannabinoid approach as key factors that have attracted him to the business. He outlines his dual focus in the role, continuing as CMO to ensure efficient clinical programs aligned with regulatory requirements and bringing a physician's perspective to the board. He suggests that his expertise in clinical development and board work positions him well to balance patient interests and financial considerations. Discussing the company's cash runway, Sowemimo-Coker says the company is funded into April 2024. She assures stakeholders that the board is actively exploring various funding options, and updates will be provided as progress unfolds. While the details remain confidential, she hints at potential updates before the end of the year. The interview showcased OCT's commitment to advancing cannabinoid-based therapies, building a strong leadership team, and maintaining transparency in financial matters. Stakeholders are eagerly anticipating further developments as OCT continues its journey towards clinical and financial success. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 20, 2023 10:24 AM Eastern Standard Time

Video

1 ... 74 75 76 77 78 ... 309